Ligand Pharmaceuticals, Inc. (SVFC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Date: November 18, 2014
Pages: 74
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: L95638C6678EN
Leaflet:

Download PDF Leaflet

Ligand Pharmaceuticals, Inc. (SVFC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary

Ligand Pharmaceuticals, Inc. (Ligand) is a biopharmaceutical company. It focuses on drug discovery and early-stage development of pharmaceutical products that cater to the unmet medical needs. Ligand's partnership agreements include programs related to the indications such as hepatitis, muscle wasting, multiple myeloma, dyslipidemia, diabetes, anemia, Alzheimer’s disease, epilepsy, FSGS and osteoporosis. The company's drug discovery and development programs are based on its gene transcription technology, principally related to Intracellular Receptors (IRs).. The company has established several alliances with many companies that include GlaxoSmithKline, Onyx Pharmaceuticals, Pfizer, Merck, Baxter International, Eli Lilly & Co., Spectrum Pharmaceuticals and Lundbeck Inc. Ligand is headquartered in San Diego, the US.

The company intends to enter into licensing agreement with other pharmaceutical and biotechnology companies and collect royalty revenue and licensing fees from them. To this end, recently the company signed a Commercial License Agreement with Sage Therapeutics Inc for commercialization of Captisol.

Ligand Pharmaceuticals, Inc. (SVFC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
  • The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
  • The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
  • Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
  • Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
  • Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company.
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Purchase
Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis For Up To US$4.5 Million
Ligand Pharma Acquires Milestones And Royalty Interests For MEDI-528 From Genaera Liquidating
Genaera Sells IL-9 To Ligand Pharma And Biotech Value Fund
Partnerships
Hovione FarmaCiencia Enters Into Co-Promotion Agreement With Ligand For Captisol Technology
Ligand Extends Its Research Agreement With Pfizer
Ligand Pharma Enters Into An Amended Agreement With GlaxoSmithKline
CyDex Pharma Extends Its Collaboration With Hovione
Metabasis Therapeutics Extends Research Agreement With Merck
Licensing Agreements
Ligand Pharma Extends Licensing Agreement With CURx Pharma for Topiramate Lamotrigine
Ligand Pharma Enters into Licensing Agreement with Avion Pharma for Captisol
Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program
Viking Therapeutics Enters into Licensing Agreement with Ligand Pharma
Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma
Ligand Pharma Enters Into Licensing Agreement With CURx Pharma For Topiramate Injection
Ligand Pharma Enters Into Licensing Agreement With Ethicor For Oral Lasofoxifene
Azure Biotech Enters Into Licensing Agreement With Ligand Pharma For Lasofoxifene
Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan
Ligand Pharma Enters Into Licencing Agreement With Merck
Ligand Pharma Enters Into Licensing Agreement With Retrophin For Dual Acting Receptor Antagonist
Ligand Pharma Enters Into Licensing Agreement With Hospira
Ligand Pharma Enters Into Licensing Agreement With Eli Lilly
Ligand Pharma Enters Into Licensing Agreement With Sage Therapeutics
Ligand Pharma Enters Into Licensing Agreement With Chiva Pharma For Fablyn
Ligand Pharma Enters Into Licensing Agreement With The Medicines Company
Ligand Enters Into Licensing Agreement With Chiva For Pradefovir And MB01733
Ligand Pharma Enters Into Sublicensing Agreement With Pfizer
Ligand Pharma Enters Into Licensing Agreement With Proximagen Group
CyDex Pharma Enters Into Licensing Agreement With University Of Kansas
Ligand Pharma Amends Licensing Agreement With Exelixis
Ligand Pharma Enters Into Licensing Agreement With ParinGenix
Glycomed Enters Into Licensing Agreement With ParinGenix
Ligand Pharma Enters Into Agreement With Trevena
Ligand Pharma Enters Into Licensing Agreement With GlaxoSmithKline
Metabasis Therapeutics Enters Into Collaboration And Licensing Agreement With Roche
Equity Offering
Ligand Pharma Completes First Tranche Of Public Offering Of Securities For US$2.7 Million
Ligand Pharma Announces Private Placement Of Common Stock For US$30 Million
Metabasis Therapeutics Completes Private Placement Of US$0.30 Million
Metabasis Therapeutics Completes Private Placement Of US$3.65 Million
Neurogen Completes Private Placement Of US$31 Million
Metabasis Therapeutics Completes Private Placement Of US$5.82 Million
Debt Offering
Ligand Pharma Prices Private Placement of 0.75% Notes Due 2019 for USD225 Million
Asset Transactions
Ligand Pharma Completes Sale Of Its Combinatorial Chemical Library To Venenum Biodesign
Neurogen Sells C5a Patent Estate And Related Assets
Acquisition
Ligand Pharma Acquires CyDex Pharma
Ligand Pharma Acquires Metabasis Therapeutics
Ligand Pharma Completes Acquisition Of Neurogen
Ligand Pharma Acquires Pharmacopeia
Ligand Pharmaceuticals, Inc. - Key Competitors
Key Employees
Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Key Facts, 2013
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Ligand Pharmaceuticals, Inc., Deals By Therapy Area, 2008 to YTD 2014
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014
Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis For Up To US$4.5 Million
Ligand Pharma Acquires Milestones And Royalty Interests For MEDI-528 From Genaera Liquidating
Genaera Sells IL-9 To Ligand Pharma And Biotech Value Fund
Hovione FarmaCiencia Enters Into Co-Promotion Agreement With Ligand For Captisol Technology
Ligand Extends Its Research Agreement With Pfizer
Ligand Pharma Enters Into An Amended Agreement With GlaxoSmithKline
CyDex Pharma Extends Its Collaboration With Hovione
Metabasis Therapeutics Extends Research Agreement With Merck
Ligand Pharma Extends Licensing Agreement With CURx Pharma for Topiramate Lamotrigine
Ligand Pharma Enters into Licensing Agreement with Avion Pharma for Captisol
Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program
Viking Therapeutics Enters into Licensing Agreement with Ligand Pharma
Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma
Ligand Pharma Enters Into Licensing Agreement With CURx Pharma For Topiramate Injection
Ligand Pharma Enters Into Licensing Agreement With Ethicor For Oral Lasofoxifene
Azure Biotech Enters Into Licensing Agreement With Ligand Pharma For Lasofoxifene
Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan
Ligand Pharma Enters Into Licencing Agreement With Merck
Ligand Pharma Enters Into Licensing Agreement With Retrophin For Dual Acting Receptor Antagonist
Ligand Pharma Enters Into Licensing Agreement With Hospira
Ligand Pharma Enters Into Licensing Agreement With Eli Lilly
Ligand Pharma Enters Into Licensing Agreement With Sage Therapeutics
Ligand Pharma Enters Into Licensing Agreement With Chiva Pharma For Fablyn
Ligand Pharma Enters Into Licensing Agreement With The Medicines Company
Ligand Enters Into Licensing Agreement With Chiva For Pradefovir And MB01733
Ligand Pharma Enters Into Sublicensing Agreement With Pfizer
Ligand Pharma Enters Into Licensing Agreement With Proximagen Group
CyDex Pharma Enters Into Licensing Agreement With University Of Kansas
Ligand Pharma Amends Licensing Agreement With Exelixis
Ligand Pharma Enters Into Licensing Agreement With ParinGenix
Glycomed Enters Into Licensing Agreement With ParinGenix
Ligand Pharma Enters Into Agreement With Trevena
Ligand Pharma Enters Into Licensing Agreement With GlaxoSmithKline
Metabasis Therapeutics Enters Into Collaboration And Licensing Agreement With Roche
Ligand Pharma Completes First Tranche Of Public Offering Of Securities For US$2.7 Million
Ligand Pharma Announces Private Placement Of Common Stock For US$30 Million
Metabasis Therapeutics Completes Private Placement Of US$0.30 Million
Metabasis Therapeutics Completes Private Placement Of US$3.65 Million
Neurogen Completes Private Placement Of US$31 Million
Metabasis Therapeutics Completes Private Placement Of US$5.82 Million
Ligand Pharma Prices Private Placement of 0.75% Notes Due 2019 for USD225 Million
Ligand Pharma Completes Sale Of Its Combinatorial Chemical Library To Venenum Biodesign
Neurogen Sells C5a Patent Estate And Related Assets
Ligand Pharma Acquires CyDex Pharma
Ligand Pharma Acquires Metabasis Therapeutics
Ligand Pharma Completes Acquisition Of Neurogen
Ligand Pharma Acquires Pharmacopeia
Ligand Pharmaceuticals, Inc., Key Competitors
Ligand Pharmaceuticals, Inc., Key Employees
Ligand Pharmaceuticals, Inc., Subsidiaries

LIST OF FIGURES

Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
Skip to top


Ask Your Question

Ligand Pharmaceuticals, Inc. (SVFC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: